Insulin resistance is a common feature of non-insulin-dependent diabetes mellitus (NIDDM) and "diabetes susceptibility genes" may be involved in this abnormality. Two potential candidate genes are the insulin receptor (IR) and the insulin-sensitive glucose transporter (GLUTT4). To elucidate whether structural defects in the IR and/or GLUT4 could be a primary cause of insulin resistance in NIDDM, we have sequenced the entire coding region of the GLUT4 gene from DNA of six NIDDM patients. Since binding properties of the IRs from NIDDM subjects are normal, we also analyzed the sequence of exons 16-22 (encoding the entire cytoplasmic domain of the IR) of the IR gene from the same six patients. When compared with the normal IR sequence, no difference was found in the predicted amino acid sequence of the IR cytoplasmic domain derived from the NIDDM patients. Sequence analysis of the GLUT-4 gene revealed that one patient was heterozygous for a mutation in which isoleucine (ATC) was substituted for valine (GTC) at position 383. Consequently, the GLUT-4 sequence at position 383 was determined in 24 additional NIDDM patients and 30 nondiabetic controls and all showed only the normal sequence. From these studies, we conclude that the insulin resistance seen in the great majority of subjects with the common form of NIDDM is not due to genetic variation in the coding sequence of the IR ft subunit, nor to any single mutation in the GLUT4 gene. Possibly, a subpopulation of NIDDM patients exists displaying variation in the GLUT-4 gene. (J.
Introduction
Although non-insulin-dependent diabetes mellitus (NIDDM)' is a heterogeneous pathophysiologic disorder, insulin resis-tance is a characteristic feature in essentially all subjects with established hyperglycemia (1) . Furthermore, recent evidence indicates that in high-risk populations, individuals destined to develop NIDDM are insulin resistant before the onset of clinically apparent hyperglycemia (2, 3) . In the prediabetic state, increased insulin secretion compensates for the insulin resistance, but when this compensating mechanism fails, hyperglycemia ensues. This suggests that insulin resistance is a primary defect of etiologic importance in the pathogenesis of this disease. The cellular basis for this insulin resistance has received considerable attention (4) , and most studies have indicated that postbinding defects are the predominant cause of the decrease in insulin action (5, 6) . Thus, insulin receptor signaling is impaired in NIDDM and decreased insulin receptor autophosphorylation and tyrosine kinase activity has been reported in fat (7, 8) , liver (9) , and skeletal muscle (10) , as well as other tissues (1 1). In addition, a decrease in insulin-stimulated glucose transport activity has been consistently observed in skeletal muscle and adipocytes from NIDDM subjects (4, 12) . Since the insulin-sensitive glucose transporter (GLUT-4) is responsible for the preponderance of insulin-mediated glucose uptake in these tissues (13, 14) , the reported decrease in glucose transport activity must involve impaired GLUT-4 function. Interestingly, although the adipocyte glucose transporter number is decreased in NIDDM (4) , recent studies have reported normal total skeletal muscle GLUT-4 levels (15) . Since skeletal muscle is the major site of in vivo glucose disposal, this indicates that impaired recruitment of GLUT-4 to the cell surface or decreased GLUT-4 intrinsic activity accounts for the component of insulin resistance owing to the glucose transport defect in NIDDM.
NIDDM has a strong genetic component (16, 17) , raising the possibility that insulin resistance is inherited in this disorder. Given that defects in both insulin receptor and GLUT-4 functions have been identified in this condition, it seemed reasonable to speculate that a molecular alteration in the genes encoding one or both of these proteins might exist. To assess this question, we have sequenced the exons comprising the entire GLUT-4 coding sequence in six NIDDM subjects, whose clinical and metabolic characteristics were typical for type II diabetic subjects. In these same patients we have sequenced the exons (16) (17) (18) (19) (20) (21) (22) that encode the cytoplasmic domain of the insulin receptor (18) . We chose this latter approach, rather than analyzing the entire receptor gene, because the functions of the cytoplasmic domain (signaling and kinase activity) are impaired in NIDDM (4), whereas properties ofthe ectodomain (binding) are normal (10, 19, 20 (3, 000 Ci/mmol) from Dupont New England Nuclear, Boston, MA; all other chemicals used were primarily from Sigma Chemical Co., St. Louis, MO.
Subjects. The clinical and metabolic characteristics of the six NIDDM subjects are presented in Table I . Subject 2 is Mexican American and the other five subjects are Caucasian. All six subjects had unequivocal fasting hyperglycemia and displayed insulin resistance as assessed by the euglycemic glucose clamp technique. Based on fasting glucose and insulin levels, body mass index, age, and clinical characteristics they represent "typical" NIDDM subjects. An additional group of 24 NIDDM patients and 30 nondiabetic controls was used in the allele-specific polymerase chain reaction (PCR) screening studies as described below. All nondiabetics were confirmed as normal on the basis of standard 75-g oral glucose tolerance tests and each ofthe additional 24 NIDDM subjects had fasting plasma glucose levels > 9.7 mmol/liter.
Preparation ofgenomic DNA from the patient's blood. Genomic DNA was isolated from peripheral blood according to standard procedures (21) .
Enzymatic amplification of genomic DNA. Five different sets of primers (Table II) were used to amplify 11 exons and adjacent introns ofthe GLUT-4 gene by PCR (22) . By using sets ofprimers as described by Seino et al. (23) End-labeling of the sequencing primer (40 pmol) was performed according to standard procedures (21) . The 32P-labeled oligonucleotides were purified by chromatography through Sephadex G-50 (21) . The eluant (100 LI) was dried in a concentrator (Speed Vac, Savant Instruments Inc., Farmingdale, NY) and dissolved in 4.8 M1 of sterile water. Sequencing reactions using Sequenase were carried out according to the protocol used by Kadowaki et al. (26) .
Allele-specific PCR amplification. For amplification of specific alleles by PCR, we used the method described by Sarkar et al. (27) . The sets of primers used for amplification of either the normal or mutant GLUT-4 gene alleles are as follows: (18) . The nucleotide sequence of the amplified DNA was then determined directly from the PCR mixture as described in the Methods section. When the sequences of exons 16-22 from the six NIDDM subjects were compared to the previously published normal insulin receptor gene sequence (18) GLUT-4 gene. The human GLUT-4 gene has been isolated and completely characterized by Bell et al. (13) . The gene spans a region of 8,000 bp on the short arm ofchromosome 17 and is composed of 11 exons and 10 introns (13) . Using the known sequence ofthe GLUT-4 gene as a guide, we selected five pairs of primers (Table II) by gel electrophoresis indicated that little nonspecific priming occurred (Fig. 1) . The nucleotide sequences of the five PCRamplified fragments were determined as described in the Methods section. In five of the patients the predicted amino acid sequence was identical to the published normal sequence (29) . The other subject (no. 4, Table I ) was heterozygous for a substitution in the GLUT-4 sequence. This patient (no. 4) displays both A and G at nucleotide position 1292 (Fig. 2) , corresponding to codon 383 in exon 9. This leads to an isoleucine (ATC) for valine (GTC) substitution in the fifth extracellular loop of the GLUT-4 protein (Fig. 3 ). This sequence difference was confirmed on three separate sequencing gels derived from three separate PCR amplifications. At nucleotide position 535 (corresponding to the third nucleotide of codon 130 [29] ), two patients were heterozygous and one subject was homozygous for a silent nucleotide polymorphism. Codon 130 was AAC and AAT (both Asn) and thus, this polymorphism did not change the amino acid sequence (data not shown). The valine --isoleucine substitution is conservative and Table III , which shows the sequence of GLUT-1, -2, -3, and -5 at codon 383, reveals leucine at position 383 in GLUT-l and isoleucine in GLUT-5. To further assess the potential significance of mutation in NIDDM, we analyzed DNA from 24 additional NIDDM patients and 30 nondiabetic subjects for the presence ofthis substitution by allele-specific PCR amplification. This method involves the use of PCR oligonucleotide primer sets that amplify either the normal or mutant allele (30) . As can be seen in Fig. 4 , both the normal (A) and mutant (A') allele-specific primer sets amplify a GLUT-4 DNA fragment of 194 bp (lanes I and 2) from the genomic DNA of the patient (no. 4) who was heterozygous for the Val383 --Ile383 mutation.
In the 30 control and 24 additional NIDDM subjects, PCR amplification of the 194-bp fragment occurred only with the normal allele primer set (A); lanes 3 and 4 show the results in representative subjects. The primer set for insulin receptor exon 22 gave rise to a 507-bp fragment in all samples, demonstrating that the absence ofmutant GLUT-4 fragments was not due to a failure of the PCR.
Discussion
In patients with established NIDDM a variety of characteristic metabolic defects exist. Among these are insulin resistance, increased hepatic glucose production, and impaired pancreatic f: cell function (1). The disease is clearly heterogeneous, and it remains unproven which of these defects is primary. However, a number of studies have examined "prediabetic" individuals from high-risk populations and have found that insulin resistance can be demonstrated before the development ofhyperglycemia and in the absence of the other metabolic defects (2, 3, (31) (32) (33) . These studies include first-degree relatives of NIDDM subjects (31), identical twins ofNIDDM subjects (32), and subjects from ethnic groups at high risk for NIDDM (33) , such as Pima Indians (2, 3). In the later population group, studies have shown that insulin resistance is inherited and predates the onset of hyperglycemia. The above-mentioned studies, as well as others (34) , establish the strong genetic contribution to the development of NIDDM as well as the importance of insulin resistance.
In the current studies, we have focused our attention on the insulin receptor gene and the gene for the insulin-sensitive glucose transporter (GLUT-4) as candidate genes. The results represent the first sequence data available in NIDDM of the GLUT-4 gene and, except for single case studies (35) (36) (37) [29] ), where the NIDDM subject was heterozygous for a conservative amino acid replacement.
from NIDDM subjects, but no alterations in the function ofthe a subunits with respect to binding affinity or specificity have been described (1) . On the other hand, studies have consistently shown a decrease in the receptor kinase activity in NIDDM patients (7) (8) (9) (10) . Although these kinase defects are reversible with weight reduction (40) and do not exist in fibroblasts cultured from NIDDM patients (41), there could be a genetic alteration in the insulin receptor rendering it susceptable to a functionally adverse post-translational change.
Since the binding functions of the insulin receptor are preserved in NIDDM, whereas kinase activity and signaling are impaired, we restricted our studies to an analysis ofthe nucleotide sequence of exons 16-22 of the insulin receptor gene. These exons encode the entire cytoplasmic domain of the receptor protein including the kinase domain and other putative signaling elements (18) .
In all six patients, the sequence ofthe insulin receptor cytoplasmic domain was entirely normal. Thus, no evidence for a genetic alteration leading to a change in the primary structure ofthe insulin receptor was found. These findings, coupled with a recent report that the full-length insulin receptor sequence was normal in an NIDDM patient (35) , lead to the conclusion that variations in the coding sequence of the insulin receptor gene do not underlie the insulin resistance in the great majority of NIDDM patients. These results are also consistent with two recent reports demonstrating a normal insulin receptor sequence in two diabetic Pima Indians (36, 37) . It should be pointed out that our results for both the insulin receptor and GLUT-4 genes relate only to alterations in the coding sequences; the possibility of regulatory defects in the flanking regions or deletion of an entire allele are not elucidated by our studies.
Although our studies demonstrate that most NIDDM patients have a normal insulin receptor sequence, they do not exclude the possibility that a small subset of patients with the NIDDM phenotype have mutations in the insulin receptor gene as a primary cause of their insulin resistance. Indeed, it is quite likely that this is the case, although this probably accounts for only a very small percentage of NIDDM patients. Thus, most patients with genetic forms ofextreme insulin resistance (type A insulin resistance, leprechaunism, Rabson Mendenhall syndrome, etc.) are homozygotes or compound heterozygotes for insulin receptor gene mutations. However, many family members ofthese patients are simple heterozygotes, and show representative results from 24 additional NIDDM patients and 30 nondiabetic subjects. As an internal positive control, all reaction mixtures contained an additional primer set for the insulin receptor exon 22 that directed the amplification of a 507-bp fragment. Genomic DNA was isolated from the peripheral blood of normal or NIDDM subjects and PCR was performed as described in Methods using either the normal (A) (lanes 1, 3, and 5) or mutant (A') (lanes 2, 4, and 6) allele-specific primer sets. Both primer sets directed the amplification of a 194-bp GLUT-4 allele-specific fragment and the mutant (A') primer set is designed to detect the Ile383 variant.
in some cases the amino acid substitutions behave as dominant negative mutations producing clinically significant insulin resistance and sometimes diabetes. The phenotype ofthese heterozygous family members is indistinguishable from NIDDM, particularly when the diabetes is discovered in later years. Possibly, mutations such as these, when coupled with other acquired abnormalities, such as obesity or ,3 cell dysfunction, produce the NIDDM syndrome and these kinds of heterozygous patients comprise the minimal estimate of the proportion of the NIDDM population associated with genetic mutations in the insulin receptor gene.
Insulin-sensitive glucose transporter (GLUT-4). At least five human glucose transporter species exist, displaying tissue specific distribution. An insulin-regulatable glucose transporter (GLUT-4) is uniquely expressed in muscle and adipose tissue and accounts for the majority of insulin-stimulated glucose transport ( 13, 14) . Evidence exists to indicate that under most physiologic circumstances the glucose transport step is rate-limiting for overall in vivo glucose uptake (42) . Consequently, defects in glucose transport could be mechanistically important to the in vivo insulin resistance in NIDDM. Indeed, decreased rates of glucose transport have been widely reported in adipocytes isolated from NIDDM subjects (43) . Most likely, this is due to a reduced number ofadipocyte GLUT-4 proteins as well as decreased intrinsic activity of the transporters (4). Skeletal muscle is responsible for 80-90% ofinsulin-stimulated glucose uptake in vivo, and decreased in vitro glucose transport has been reported in skeletal muscle from NIDDM subjects (44) . These findings indicate that impaired glucose transport is an important factor in the insulin resistance ofNIDDM. However, in skeletal muscle, total cellular GLUT-4 levels (15), as well as GLUT-4 mRNA (15) are normal in NIDDM. This indicates that the decreased skeletal muscle glucose transport in NIDDM is due to impaired recruitment (translocation) of GLUT-4 transporters to the cell surface, a decrease in GLUT-4 intrinsic activity, or both. Given these findings plus the genetic contribution to NIDDM, a primary defect in GLUT-4 structure seemed possible.
To assess this hypothesis, we have used PCR and direct sequencing to amplify and sequence all 1 GLUT-4 exons (13) from genomic DNA derived from six NIDDM subjects. Our results show that the GLUT-4 gene sequence was entirely normal in five ofthe six patients. One subject (no. 4) was heterozygous for an A for G mutation at nucleotide position 1292 leading to an isoleucine for valine substitution at codon 383 which is in the fifth extracellular loop ofthe GLUT-4 protein (Fig. 3) . However, this is a structurally conservative substitution and among the five human glucose transporter species, two (GLUT-1 and GLUT-50 already contain leucine (GLUT-1) and isoleucine (GLUT-5) rather than valine at this position.
Since functional studies oftransfected GLUT-4 cDNAs can be problematic (44) , we elected to pursue whether this substitutions were significant in the etiology of NIDDM, by analyzing DNA from an additional 24 NIDDM patients and 30 nondiabetic subjects. Allele-specific PCR amplification was used to detect the presence of this substitution, and these additional subjects showed only wild-type sequence at this position. Thus, of the 60 NIDDM alleles analyzed, the frequency of the polymorphism identified was only one in 60 and it was not detected in 30 nondiabetic subjects. From this, we conclude that this specific genetic variant is uncommon and could only represent a very small subset of the NIDDM population. Given the low frequency of this variant in the NIDDM group, studies in a greatly expanded number of normals would be necessary to determine whether its frequency is lower in normal versus NIDDM subjects.
The simplest interpretation of our data is that substitutions in GLUT-4 are unusual in NIDDM and, therefore, do not contribute to this disease in the great majority of NIDDM patients. However, we should also point out that although our results provide evidence that no single mutation in the GLUT-4 gene exists in a high proportion of NIDDM subjects, we did identify one substitution among our six subjects. This raises the theoretical possibility that GLUT-4 gene mutations exist in a small, but significant, subgroup of NIDDM patients, but that no single mutation will be common. Insofar as any GLUT-4 substitution is functionally significant, it could have importance to the NIDDM state.
If inherited structural defects in the insulin receptor and GLUT-4 genes are not the primary cause of cellular insulin resistance in most NIDDM subjects, then what defects might be involved? Insulin action is obviously a complex process involving multiple sequential steps. Our data would indicate that, if a common genetic defect in the insulin action cascade exists, it is located at a step(s) between the insulin receptor and GLUT-4. Since the total amount of skeletal muscle protein is normal in NIDDM (15) , it is reasonable to propose that a defect in recruitment of transporters to the cell surface exists. This implies a postreceptor signaling abnormality in this aspect of insulin action. Since not all aspects of insulin action are equally resistant in NIDDM, it is possible that such a defect lies in one or more proteins involved in the arm ofpostreceptor insulin signaling related to glucose metabolism. Perhaps NIDDM is multigenic and subgroups of patients will display genetic defects in different proteins, in aggregate accounting for the insulin resistance in NIDDM, consistent with the heterogeneous nature of this disease. Note added in proof. Based on preliminary data reported in abstract form (1991. Diabetes. 40:158A), a valine for methionine mutation at GLUT-4 position 126 was initially identified in one of our patients. However, subsequent experiments showed the sequence to be normal in this patient.
